Related Experiment Videos
Current treatment strategies for rheumatoid arthritis
1Division of Rheumatology and Internal Medicine, Mayo Clinic Rochester, Minn 55905, USA.
Abstract:
The management of rheumatoid arthritis has changed considerably during the past 15 years. Current strategies emphasize the need for early diagnosis and therapeutic intervention based on the use of disease-modifying antirheumatic drugs. The advent of agents that are more tailored to inhibit the specific disease processes will profoundly affect management. Immunogenetic studies may eventually assist in identifying subgroups of patients with rheumatoid arthritis who have more aggressive disease and who require a more aggressive treatment approach.
Insights
Rheumatoid arthritis management now focuses on early diagnosis and disease-modifying antirheumatic drugs. Future treatments may use immunogenetics to personalize care for aggressive rheumatoid arthritis cases.
Area of Science:
- Rheumatology and Immunology
Background:
- Rheumatoid arthritis (RA) management has evolved significantly over the last 15 years.
- Current RA treatment emphasizes early diagnosis and intervention with disease-modifying antirheumatic drugs (DMARDs).
Purpose of the Study:
- To discuss the impact of emerging targeted therapies on RA management.
- To explore the potential role of immunogenetics in tailoring treatment approaches for RA patients.
Main Methods:
- Review of current literature and clinical strategies in rheumatoid arthritis management.
- Discussion of advancements in targeted biologic agents and immunogenetic research.
Main Results:
- The introduction of targeted therapies promises to revolutionize RA treatment by inhibiting specific disease pathways.
- Immunogenetic studies hold potential for identifying patient subgroups who may benefit from more aggressive treatment protocols.
Conclusions:
- The future of rheumatoid arthritis management involves personalized medicine, informed by immunogenetic insights.
- Tailored therapeutic interventions are expected to improve outcomes for patients with aggressive disease phenotypes.